Previous 10 | Next 10 |
Forty Seven, Inc. (FTSV) Q3 2019 Earnings Conference Call November 12, 2019 8:00 AM ET Company Participants Michael Horowicz – Stern Investor Relations Mark McCamish – Chief Executive Officer Ann Rhoads – Chief Financial Officer Mark Chao – Founder a...
Forty Seven (NASDAQ: FTSV ): Q3 GAAP EPS of -$0.38 misses by $0.10 . More news on: Forty Seven, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- On-Track to Initiate Potential Registration-Enabling Trials in MDS and DLBCL in 1Q 2020 -- -- Entered into Collaboration with bluebird bio to Evaluate Antibody-Based Conditioning Regimen in Combination with LentiGlobin -- -- Management to Host Conference Call at 8:00 a.m. ET Today -...
MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that updated data from its ongoing Phase 1b study evaluating ...
MENLO PARK, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that it will host a live conference call and webcast at 8:00 a...
MENLO PARK, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executiv...
Biotech stocks rarely perform well during the summer months, and 2019 has proven to be no exception in regards to this historical trend line. The iShares Nasdaq Biotechnology ETF , for example, has now fallen by nearly 2% since the official start of summer. Biotech equities, however, d...
ANI Pharmaceuticals (NASDAQ: ANIP ) initiated with Buy rating and $76 (9% upside) price target at Guggenheim. More news on: ANI Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
MENLO PARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executiv...
Thinly traded micro cap Forty Seven ( FTSV -0.9% ) is down on below-average volume on the heels of the FDA designating lead candidate magrolimab (formerly 5F9) for Fast Track review for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). More news on: For...
News, Short Squeeze, Breakout and More Instantly...
The ongoing COVID-19 pandemic has caused significant disruptions to the global economy, as well as grievances for families witnessing their loved ones die from the virus. Fortunately, there's finally a light at the end of the tunnel as one investigative treatment has revealed potential efficacy ...
For years, Gilead Sciences ' (NASDAQ: GILD) stock price has been rather disappointing for investors hoping for long-term capital appreciation. While shares do boast an impressive 3.63% dividend yield, the company's revenues have experienced an enormous decline from 2015 onwards, falling over ...
Shares of Forty Seven (NASDAQ: FTSV) climbed 64.5% in March, according to data from S&P Global Market Intelligence . The immuno-oncology specialist's stock skyrocketed early in the month after it was announced that the company was on track to be purchased by Gilead Sciences...